FATE THERAPEUTICS INC Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax
FATE THERAPEUTICS INC (FATE) had Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax of $51.00 thousand as of 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2019-11-05
- 2019-09-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $51.00K.
- 2019-06-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $93.00K.
- 2016-09-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $3.00K.
- 2016-06-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $11.00K.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2019-09-30 | $51.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $93.00K 10-Q · filed 2019-08-06 |
| 2016-09-30 | $3.00K 10-Q · filed 2016-11-07 |
| 2016-06-30 | $11.00K 10-Q · filed 2016-08-08 |
| 2016-03-31 | $14.00K 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |